Hyaluronic acid-targeted protein capped AMSN for inhibiting tumour growth and side effects by the controlled release of curcumin and doxorubicin

Ample attention has focused on Hyaluronic acid (HA) targeted Soy protein (SOY) capped Aminated Mesoporous Silica (AMSN), a novel combinatorial approach for the effective co-delivery of curcumin (CUR) and doxorubicin (DOX) for colon cancer. CUR was loaded in the inner core of AMSN via electrostatically followed by capping with SOY. HA acts as a targeting ligand and DOX carrier. The modified structural elucidation of drug carrier was done by FT-IR, XRD, DLS, EDX and BET adsorption isotherm. The morphological detection was carried out by FE-SEM, AFM and TEM analyses.The dual drug delivery system (DDDS) having maximum drug loading efficiency of 81.0 % for DOX and 70.0 % for CUR. The pH dependent release study shows maximum release (64.2 % CUR and 80.0 % DOX) at tumour pH. The effective haemolytic activity (<3.0 %) and antioxidant property (>70.0 %) reveal the practical applicability of DDDS. MTT assay shows 25.0 % anticancer activity in DLD-1 human colon cancer cell lines and no toxic to cardiac cells (H9C2), which was further confirmed by apoptosis assay. Material without drug shows < 90.0 % viability in (L929) normal cells confirmed the non-toxic nature and proved the novel potency towards drug delivery applications.